Skip to main content
SpringerLink
Log in

Androgen Receptor Gene Mutations in Prostate Cancer

Implications for Disease Progression and Therapy

  • Review Article
  • Clinical Pharmacology
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Recent studies indicate that androgen receptors are present in all histological types of prostatic tumours, in relapsed prostatic carcinomas and in tumour metastases, even those obtained from patients in whom endocrine therapy was unsuccessful. Several research groups have asked whether structurally altered androgen receptors might be present in human prostatic tumours.

The first androgen receptor mutation in prostate cancer was detected in the tumour cell line LNCaP. The frequency of androgen receptor mutations in primary tumours of the prostate is relatively low. In contrast, a high frequency of mutations has been reported in bone metastases from patients who did not respond to endocrine therapy. This fact may reflect genetic instability in these late tumour stages. Mutant androgen receptors detected in human prostate cancer cells are ‘promiscuous receptors’; that is, they are activated not only by synthetic and testicular androgens, but also by adrenal androgens, products of dihydrotestosterone metabolism, estrogenic and progestagenic steroids, and even by nonsteroidal anti-androgens.

Interestingly, the nonsteroidal antiandrogens hydroxyflutamide and nilutamide, but not bicalutamide, have been reported to have agonistic effects at mutant androgen receptors. It is speculated that the existence of androgen receptor mutations may explain, at least in part, the ‘antiandrogen withdrawal syndrome’: a temporary improvement in a subpopulation of prostate cancer patients following cessation of an antiandrogen from a therapeutic protocol. Further studies on androgen receptor alterations in prostate cancer should focus on metastatic specimens obtained from the late stages of this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Boring CC, Squires TS, Tong T. Cancer statistics. CA Cancer J Clin 1993; 43: 7–26

    Article  PubMed  CAS  Google Scholar 

  2. Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124: 1011–7

    Google Scholar 

  3. Chang C, Kokontis J, Liao S. Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci U S A 1988; 85: 7211–5

    Article  PubMed  CAS  Google Scholar 

  4. Tan JA, Joseph DR, Quarmby VE, et al. The rat androgen receptor: primary structure, autoregulation of its messenger ribonucleic acid, and immunocytochemical localization of the receptor protein. Mol Endocrinol 1988; 2: 1276–85

    Article  PubMed  CAS  Google Scholar 

  5. Trapman J, Klaassen P, Kuiper GGJM, et al. Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochem Biophys Res Commun 1988; 153: 241–8

    Article  PubMed  CAS  Google Scholar 

  6. Tilley WD, Marcelli M, Wilson JD, et al. Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci U S A 1989; 86: 327–31

    Article  PubMed  CAS  Google Scholar 

  7. Jenster G, van der Korput J, van Vroonhoven C, et al. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 1991; 5: 1396–404

    Article  PubMed  CAS  Google Scholar 

  8. Simental JA, Sar M, Wilson EM. Domain functions of the androgen receptor. J Steroid Biochem Mol Biol 1992; 43: 37–41

    Article  PubMed  CAS  Google Scholar 

  9. Husmann DA, Wilson CM, McPhaul MJ, et al. Antipeptide antibodies to two distinct regions of the androgen receptor protein to the nuclei of target cells in the rat and human prostate. Endocrinology 1990; 126: 2359–68

    Article  PubMed  CAS  Google Scholar 

  10. Veldscholte J, Berrevoets CA, Brinkmann AO, et al. Antiandrogens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 1992; 31: 2393–9

    Article  PubMed  CAS  Google Scholar 

  11. Wong CI, Zhou ZX, Sar M, et al. Steroid requirement for androgen receptor dimerization and DNA binding: modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains. J Biol Chem 1993; 268: 19004–12

    PubMed  CAS  Google Scholar 

  12. Page MJ, Parker MG. Effect of androgen on the transcription of rat prostatic binding protein genes. Mol Cell Endocrinol 1982; 28: 343–55

    Article  Google Scholar 

  13. Rennie P, Bruchovsky N, Leco K, et al. Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 1993; 7: 23–36

    Article  PubMed  CAS  Google Scholar 

  14. Riegman P, Vlietstra R, van der Korput J, et al. The promoter of the prostate specific antigen contains a functional androgen responsive element. Mol Endocrinol 1991; 5: 1921–30

    Article  PubMed  CAS  Google Scholar 

  15. Riegman P, Vlietstra R, van der Korput J, et al. Identification and androgen regulated expression of two major human glandular kallikrein-1 (hGK-1) mRNA species. Mol Cell Endocrinol 1991; 76: 181–90

    Article  PubMed  CAS  Google Scholar 

  16. Murtha P, Tindall DJ, Young C. Androgen induction of a human prostate specific kallikrein hKLK2: characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry 1993; 32: 6459–64

    Article  PubMed  CAS  Google Scholar 

  17. Adler AJ, Danielsen M, Robins DM. Androgen specific gene activation via a consensus glucocorticoid response element is determined by interaction with non receptor factors. Proc Natl Acad Sci U S A 1992; 89: 11660–3

    Article  PubMed  CAS  Google Scholar 

  18. Perry JE, Tindall DJ. Androgens regulate the expression of proliferating cell nuclear antigen posttranscriptionally in the human prostate cancer cell line LNCaP. Cancer Res 1996; 56: 1539–44

    PubMed  CAS  Google Scholar 

  19. Barrack ER, Tindall DJ. A critical evaluation of the use of androgen receptor assays to predict the androgen responsiveness of prostatic cancer. Prog Clin Biol Res 1987; 239: 155–87

    PubMed  CAS  Google Scholar 

  20. Klocker H, Culig Z, Hobisch A, et al. Androgen receptor alterations in prostatic carcinoma. Prostate 1994; 25: 266–73

    Article  PubMed  CAS  Google Scholar 

  21. Ruizeveld de Vinter JA, Trapman J, Brinkmann AO, et al. Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J Pathol 1990; 161: 329–32

    Google Scholar 

  22. Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study of androgen receptors in metastatic prostate cancer — comparison of receptor content and response to therapy. Cancer 1991; 67: 3057–64

    Article  PubMed  CAS  Google Scholar 

  23. Van der Kwast TH, Schalken J, Ruizeveld de Vinter JA, et al. Androgen receptors in endocrine therapy-resistant human prostate cancer. Int J Cancer 1991; 48: 189–93

    Article  PubMed  Google Scholar 

  24. Ruizeveld de Vinter JA, Janssen PJA, Sleddens HMEB, et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 1994; 144: 735–46

    Google Scholar 

  25. Hobisch A, Culig Z, Radmayr C, et al. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995; 55: 3068–72

    PubMed  CAS  Google Scholar 

  26. Hobisch A, Culig Z, Radmayr C, et al. Androgen receptor status of lymph node metastasis from prostatic carcinoma. Prostate 1996; 29: 129–36

    Article  Google Scholar 

  27. Kleinerman DI, Troncoso P, Pisters LL, et al. Expression and structure of the androgen receptor in bone metastases of hormone refractory prostate cancer [abstract]. J Urol 1996; 155: 626A

    Google Scholar 

  28. Quarmby VE, Beckman WC, Cooke DB, et al. Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma. Cancer Res 1990; 50: 735–9

    PubMed  CAS  Google Scholar 

  29. Tilley WD, Wilson CM, Marcelli M, et al. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990; 50: 5382–6

    PubMed  CAS  Google Scholar 

  30. Culig Z, Klocker H, Eberle J, et al. DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 1993; 22: 11–22

    Article  PubMed  CAS  Google Scholar 

  31. Qigley CA, De Bellis A, Marschke KB, et al. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 1995; 16: 271–321

    Google Scholar 

  32. Horoszewicz JS, Leoung SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43: 1809–18

    PubMed  CAS  Google Scholar 

  33. Wilding G, Chen M, Gelmann EP. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989; 14: 103–15

    Article  PubMed  CAS  Google Scholar 

  34. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990; 17: 534–40

    Article  Google Scholar 

  35. Harris SE, Rong Z, Harris MA, et al. Androgen receptor in human prostate carcinoma LNCaP/Adep cells contains a mutation which alters the specificity of the steroid-dependent transcriptional activation region [abstract]. In: Bell L, editor. Proceedings of the 72nd Annual Meeting of the Endocrine Society: Atlanta (GA). Bethesda (MD): The Endocrine Society, 1990

  36. Montgomery BT, Young CYF, Bilhartz DL, et al. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line. Prostate 1992; 21: 63–73

    Article  PubMed  CAS  Google Scholar 

  37. Quarmby VE, Yarbrough WG, Lubahn DB, et al. Autologous down-regulation of androgen receptor messenger ribonucleic acid. Mol Endocrinol 1990; 5: 1921–30

    Google Scholar 

  38. Henttu P, Vihko P. Steroids inversely affect the biosynthesis and secretion of human prostatic acid phosphatase and prostatespecific antigen in the LNCaP cell line. J Steroid Biochem Mol Biol 1992; 41: 349–60

    Article  PubMed  CAS  Google Scholar 

  39. Newmark JR, Hardy DO, Tonb DC, et al. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A 1992; 89: 6319–23

    Article  PubMed  CAS  Google Scholar 

  40. Culig Z, Hobisch A, Cronauer MV, et al. Mutant androgen receptor detected in an advanced stage of prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993; 7: 1541–50

    Article  PubMed  CAS  Google Scholar 

  41. Suzuki H, Sato N, Watabe Y, et al. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 1993; 46: 759–63

    Article  PubMed  CAS  Google Scholar 

  42. Castagnaro M, Yandell DW, Dockhorn Dworniczak B, et al. Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer. Verh Dtsch Ges Pathol 1993; 77: 119–23

    PubMed  CAS  Google Scholar 

  43. Elo JP, Kvist L, Leinonen K, et al. Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J Clin Endocrinol Metab 1995; 80: 3494–500

    Article  PubMed  CAS  Google Scholar 

  44. Evans BAJ, Harper ME, Daniells CE, et al. Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis. Prostate 1996; 28: 162–71

    Article  PubMed  CAS  Google Scholar 

  45. Sharief Y, French FS, Mohler JL, et al. The androgen receptor and androgen-independent prostatic carcinoma [abstract]. J Urol 1996; 155: 515A

    Article  Google Scholar 

  46. Uchida T, Wang C, Ohori M, et al. Infrequent androgen receptor gene mutations in prostatic cancer [abstract]. J Urol 1996; 155: 624A

    Article  Google Scholar 

  47. Gaddipati JP, McLeod DG, Heidenberg HB, et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 1994; 54: 2861–4

    PubMed  CAS  Google Scholar 

  48. Tilley WD, Buchanan G, Hickey T, et al. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996; 2: 277–85

    PubMed  CAS  Google Scholar 

  49. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332: 1393–8

    Article  PubMed  CAS  Google Scholar 

  50. Suzuki H, Akakura K, Komiya A, et al. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 1996; 28: 153–8

    Article  Google Scholar 

  51. Klocker H, Kaspar F, Eberle J, et al. Point mutation in the DNA binding domain of the androgen receptor in two families with Reifenstein syndrome. Am J Hum Genet 1992; 50: 1318–27

    PubMed  CAS  Google Scholar 

  52. Batch JA, Williams DM, Davies HR, et al. Androgen receptor gene mutations identified by SSCP in fourteen subjects with androgen insensitivity syndrome. Hum Mol Genet 1992; 1: 497–503

    Article  PubMed  CAS  Google Scholar 

  53. Peterziel H, Culig Z, Stober J, et al. Mutant androgen receptors in prostatic tumors distinguish between amino acid sequence requirements for transactivation and ligand binding. Int J Cancer 1995; 63: 544–50

    Article  PubMed  CAS  Google Scholar 

  54. Bubley G, Fenton M, Fertig A, et al. The hormonal sensitivity of androgen receptor (AR) mutations derived from human tumors [abstract]. Cancer Res 1996; 37: 1680A

    Google Scholar 

  55. Tan J, Sharief J, Hamil G, et al. Altered ligand specificity of a mutant androgen receptor (AR) in the androgen-dependent human prostate cancer xenograft, CWR-22: comparison with the LNCaP mutant AR [abstract]. J Urol 1996; 155: 340A

    Google Scholar 

  56. Culig Z, Stober J, Gast A, et al. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone. Cancer Detect Prev 1996; 20: 68–75

    PubMed  CAS  Google Scholar 

  57. Yuan S, Trachtenberg J, Mills GB, et al. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 1993; 533: 1304–11

    Google Scholar 

  58. Marcelli M, Haidacher J, Plymate SR, et al. Altered growth and insulin-like growth factor-binding protein-3 production in PC3 prostate carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid. Endocrinology 1995; 136: 1040–8

    Article  PubMed  CAS  Google Scholar 

  59. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 1566–72

    PubMed  CAS  Google Scholar 

  60. Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43: 408–10

    Article  PubMed  CAS  Google Scholar 

  61. Dawson NA, McLeod DG. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 1995; 153: 1946–7

    Article  PubMed  CAS  Google Scholar 

  62. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome. Cancer 1995; 76: 1428–34

    Article  PubMed  CAS  Google Scholar 

  63. Scher HI, Bentel JM, Buchanan G, et al. Androgen receptor expression in androgen-independent prostate cancer: relation to flutamide withdrawal [abstract]. Cancer Res 1996; 37: 1672A

    Google Scholar 

  64. Schoneberg MP, Hakimi JM, Wang S, et al. Microsatellite mutation (CAG 24→18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 1994; 198: 74–80

    Article  Google Scholar 

  65. Takahashi H, Furusato M, Allsbrock Jr WC, et al. Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. Cancer Res 1995; 55: 1621–4

    PubMed  CAS  Google Scholar 

  66. Kokontis J, Takakura K, Hay N, et al. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994; 54: 1566–73

    PubMed  CAS  Google Scholar 

  67. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the AR gene and progression of human prostate cancer. Nature Genet 1995; 9: 401–6

    Article  PubMed  CAS  Google Scholar 

  68. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostate tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Cancer Res 1994; 54: 5474–8

    PubMed  CAS  Google Scholar 

  69. Ikonen T, Palvimo JJ, Kallio PJ, et al. Stimulation of androgenregulated transactivation by modulators of protein phosphorylation. Endocrinology 1994; 125: 1359–66

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Laboratory, Department of Urology, University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria

    Zoran Culig, Alfred Hobisch, Marcus V. Cronauer, Christian Radmayr, Georg Bartsch & Helmut Klocker

  2. Department of Pathology, University of Innsbruck, Innsbruck, Austria

    Anton Hittmair

Authors
  1. Zoran Culig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alfred Hobisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anton Hittmair
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marcus V. Cronauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christian Radmayr
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Georg Bartsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Helmut Klocker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Culig, Z., Hobisch, A., Hittmair, A. et al. Androgen Receptor Gene Mutations in Prostate Cancer. Drugs & Aging 10, 50–58 (1997). https://doi.org/10.2165/00002512-199710010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199710010-00005

Keywords

Search

Navigation